US FDA advisers vote in favor of recommending COVID vaccines target XFG variant
28/05/2026 19:30
US FDA advisers vote in favor of recommending COVID vaccines target XFG variant May 28 (Reuters) - The U.S. FDA's advisory panel on Thursday voted in favor of recommending that COVID-19 vaccines for the 2026-2027 immunization campaign should target the dominant JN.1 lineage XFG variant.
Eight out of nine panel members voted in favor of the recommendation, while one abstained.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials